FDA Approves First Gene Therapy for Adults With Hemophilia B
MONDAY, Nov. 28, 2022 (HealthDay News) — The U.S. Food and Drug Administration has approved Hemgenix (etranacogene dezaparvovec) for the treatment of hemophilia B in adults.Hemgenix, an adeno-associated virus vector-based gene therapy, is administere…
Learn MoreA Gene Therapy for Hemophilia That Costs $3.5 Million Gets FDA Approval
WEDNESDAY, Nov. 23, 2022 (HealthDay News) — People with one form of the genetic blood disorder hemophilia now have a one-time treatment with a $3.5 million price tag.The U.S. Food and Drug Administration approved the new gene therapy Hemgenix on Nov….
Learn MoreFDA Approves Drug Combo for Metastatic Non-Small Cell Lung Cancer
TUESDAY, Nov. 15, 2022 (HealthDay News) — The U.S. Food and Drug Administration approved the combination of tremelimumab (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer …
Learn MoreFDA Approves Dupixent for Prurigo Nodularis
FRIDAY, Sept. 30, 2022 (HealthDay News) — The U.S. Food and Drug Administration approved Dupixent (dupilumab) as the first treatment for adults with prurigo nodularis, according to Regeneron Pharmaceuticals.Prurigo nodularis, a chronic, debilitating …
Learn MoreFDA Approves Dupixent for Prurigo Nodularis
FRIDAY, Sept. 30, 2022 (HealthDay News) — The U.S. Food and Drug Administration approved Dupixent (dupilumab) as the first treatment for adults with prurigo nodularis, according to Regeneron Pharmaceuticals.Prurigo nodularis, a chronic, debilitating …
Learn MoreFDA Approves Dupixent for Prurigo Nodularis
FRIDAY, Sept. 30, 2022 (HealthDay News) — The U.S. Food and Drug Administration approved Dupixent (dupilumab) as the first treatment for adults with prurigo nodularis, according to Regeneron Pharmaceuticals.Prurigo nodularis, a chronic, debilitating …
Learn MoreFDA Approves New ALS Drug Despite Uncertain Data
FRIDAY, Sept. 30, 2022 (HealthDay News) — The U.S. Food and Drug Administration on Thursday gave its approval to a new drug for amyotrophic lateral sclerosis (ALS). But approval of the drug, called Relyvrio (sodium phenylbutyrate/taurursodiol), is bo…
Learn MoreFDA Approves New ALS Drug Despite Uncertain Data
FRIDAY, Sept. 30, 2022 (HealthDay News) — The U.S. Food and Drug Administration on Thursday gave its approval to a new drug for amyotrophic lateral sclerosis (ALS). But approval of the drug, called Relyvrio (sodium phenylbutyrate/taurursodiol), is bo…
Learn MoreFDA Approves New ALS Drug Despite Uncertain Data
FRIDAY, Sept. 30, 2022 (HealthDay News) — The U.S. Food and Drug Administration on Thursday gave its approval to a new drug for amyotrophic lateral sclerosis (ALS). But approval of the drug, called Relyvrio (sodium phenylbutyrate/taurursodiol), is bo…
Learn MoreFDA Approves New ALS Drug Despite Uncertain Data
FRIDAY, Sept. 30, 2022 (HealthDay News) – The U.S. Food and Drug Administration on Thursday gave its approval to a new drug for ALS (amyotrophic lateral sclerosis), also known as Lou Gehrig’s disease.But approval of the drug, called Relyvrio, is bound…
Learn More